Mechanism of action (MoA) study 3month oral dosing of Vilprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy

Critchley, Hilary (Principal Investigator)

Deanery of Clinical Sciences

Status	Finished
Effective start/end date	1/09/17 → 31/08/19

Funding

UK industry, commerce and public corporations: £775,187.00

Bayer study 15791 - Mechanism of action (MoA) study 3month oral dosing of Vilaprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy
Critchley, H. (Owner), Murray, C. (Creator), Chodankar, R. (Creator), Murray, A. (Creator), Nicol, M. (Creator) & Williams, A. (Creator), Edinburgh DataVault, 2021
DOI: 10.7488/f58131b2-2532-47a6-8a50-a4a6aafd82d2
Dataset